Rapid Micro Biosystems CEO Rob Spignesi to Speak at the 2022 PDA/FDA Joint Regulatory Conference
September 12 2022 - 9:00AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced that its Chief Executive Officer, Robert Spignesi, will
speak at the 2022 PDA/FDA Joint Regulatory Conference on Wednesday,
September 14th.
Mr. Spignesi’s session, “The Microbiology Lab of the 21st
Century: Efficiency and Reliability Through Automation and
Digitization,” will cover the evolving challenges global
pharmaceutical companies face, including, among other things, the
rise of new complex therapies, the need for faster and leaner
manufacturing processes that also meet regulatory requirements, as
well as how to manage risks and improve data Integrity. Mr.
Spignesi will also discuss how automation and digitization can help
modernize a critical, regulated aspect of the global pharmaceutical
manufacturing process in order to bring microbial quality control
into the 21st century.
Mr. Spignesi’s session will begin at 7:15 AM ET and run
approximately 25 minutes. Mr. Spignesi will then be joined by Kham
Nguyen, Rapid Micro Biosystems’ Senior Director, Global Field
Service and Validation, for a Q&A session.
Investors and other interested parties are invited to register
and listen to a live webcast of the session using this link:
https://www.pda.org/global-event-calendar/event-detail/2022-pda-joint-regulatory-conference.
A recording of this webcast will be available to registered
attendees for 60 days.
About the PDA/FDA Joint Regulatory
Conference
The Parenteral Drug Association (“PDA”) and the U.S. Food and
Drug Administration (“FDA”) are co-sponsoring the PDA/FDA Joint
Regulatory Conference, now in its 31st year. The conference
emphasizes the role of effective quality systems in ensuring an
ongoing state of control throughout the pharmaceutical product
lifecycle by vigilantly managing risks to manufacturing and
quality. A link to the conference website and registration
information for this event is available (here).
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology
company providing mission critical automation solutions to
facilitate the efficient manufacturing and fast, safe release of
healthcare products such as biologics, vaccines, cell and gene
therapies, and sterile injectables. The Company’s flagship Growth
Direct system automates and modernizes the antiquated, manual
microbial quality control (“MQC”) testing workflows used in the
largest and most complex pharmaceutical manufacturing operations
across the globe. The Growth Direct system brings the quality
control lab to the manufacturing floor, unlocking the power of
in-line/at-the-line MQC automation to deliver faster results,
greater accuracy, increased operational efficiency, better
compliance with data integrity regulations, and quicker decision
making, that customers rely on to ensure safe and consistent supply
of important healthcare products. The Company is headquartered and
has U.S. manufacturing in Lowell, Massachusetts, with global
locations in Lexington, Massachusetts, Switzerland, Germany, and
the Netherlands. For more information, please visit
www.rapidmicrobio.com or follow the company on Twitter at
@rapidmicrobio or on LinkedIn.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jul 2023 to Jul 2024